Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | ARNT | P27540 | 2/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21307026 | 0.86 | TAS1R3 (0.34) | TAS1R3TAS1R1TAS1R2ARNTEPAS1 | |
| SCHEMBL21294766 | 0.75 | PIN1 (0.37) | — | |
| SCHEMBL21296540 | 0.75 | PIN1 (0.37) | — | |
| SCHEMBL21296534 | 0.74 | KMT2A (0.38) | — | |
| SCHEMBL21294672 | 0.69 | SCN9A (0.47) | TAS1R3TAS1R1TAS1R2GRM4 | |
| SCHEMBL21294930 | 0.68 | IRAK4 (0.39) | — | |
| SCHEMBL21294822 | 0.68 | AKT1 (0.38) | — | |
| SCHEMBL21294804 | 0.67 | LMNA (0.41) | — | |
| SCHEMBL21311638 | 0.66 | HTR1A (0.39) | ARNTEPAS1 | |
| SCHEMBL21306631 | 0.64 | KAT6A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | ASAH2, ACER2, PCSK9 | TAS1R3 4539/4885TAS1R1 4544/4885TAS1R2 4594/4885 |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | TRPV1, HCN4, TRPA1 | TAS1R3 2400/4885TAS1R1 2865/4885TAS1R2 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.